Skip to main content

Coal India shares hit all-time low; ICICI Securities maintains buy call

Brokerage firm ICICI Securities has a buy call on the stock with a target price of Rs 258.

Shares of Coal India (CIL) fell over 2 percent to hit their all-time low of Rs 118.85 in intraday trade on BSE on September 22.

As per analysts' views, the company may witness de-growth in production during the current fiscal as its output is likely to fall below 600 million tonnes amid subdued demand.

Analysts of brokerage firm Motilal Oswal projected production of 582 million tonne for Coal India and off-take of 565 million tonnes in FY21.

Brokerage firm ICICI Securities has a buy call on the stock with a target price of Rs 258.

RELATED NEWS

"We maintain our buy rating and target price of Rs 258 valuing CIL on a DCF basis with peak production of 850mnte from FY29E onwards. Although our volume estimate for FY21E remains at 580mnte, CIL is confident of exceeding it, which we are positive upon if the Sep’20 performance continues till Nov’20," said ICICI Securities.

ICICI Securities highlighted that CIL continues to be the lowest-cost coal producer globally, and with several measures being taken to further rationalise cost and infrastructure development, cost per ton is expected to further decline.

CIL targets to reach 1btpa production by FY24, which translates into a CAGR of 13.5 percent from FY20 (602mnte). The company is investing in several infrastructure projects to improve evacuation and mechanise production in order to reach this target, ICICI Securities said.

Shares of Coal India traded 1.44 percent lower at Rs 119.95 on BSE at 12:05 hours.

Disclaimer: The views and investment tips expressed by investment experts on SD Solutions are their own and not that of the website or its management. SD Solutions advises users to check with certified experts before taking any investment decisions.

Source - Moneycontrol.com

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more